Ipamorelin #

• Acronym: Ipamorelin
• Amino Acid Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2 (Aib = aminoisobutyric acid, 2-Nal = 2-Naphthylalanine)
• Primary Functions and Actions:
  • Stimulates the release of growth hormone (GH).
  • Does not significantly increase appetite or cortisol levels compared to GHRP-6.
• Mechanism of Action:
  • Ipamorelin is a selective growth hormone secretagogue.
  • It binds to the ghrelin receptor in the pituitary gland, stimulating GH release.
  • It has fewer side effects related to appetite and cortisol compared to other GHRPs.
• Systems Activated:
  • Endocrine System: Primarily affects the growth hormone axis.
• Dosage and Timing:
  • Common dosages range from 200-300 mcg, one to three times per day.
  • Administered via subcutaneous injection.
  • Often taken before meals or before bedtime.
• Contraindications and Side Effects:
  • Potential side effects are minimal but can include headache or dizziness.
  • Contraindicated in individuals with active cancer or a history of cancer.
• Potential Uses:
  • Increasing muscle mass
  • Reducing body fat
  • Improving sleep
• References:
  • PMID: 9861593, PMID: 11713252
• PMID: 9861593 – [Endocrinology. 1998 Dec;139(12):5262-9.] – Ipamorelin, a novel growth hormone-releasing peptide, selectively stimulates growth hormone secretion in domestic pigs. https://pubmed.ncbi.nlm.nih.gov/9861593/
• PMID: 11713252 – [Eur J Endocrinol. 2001 Nov;145(5):605-11.] – The GH-releasing effect of ipamorelin is potentiated by GHRH in man. https://pubmed.ncbi.nlm.nih.gov/11713252/

#

Article Summaries #

PMID: 9861593 #

This study focused on Ipamorelin, a newly discovered growth hormone-releasing peptide (GHRP), and its ability to stimulate growth hormone secretion in domestic pigs. The researchers aimed to evaluate how effectively Ipamorelin could promote the release of growth hormone compared to other peptides.

The results demonstrated that Ipamorelin selectively and effectively stimulated growth hormone release in the pigs tested. The peptide’s targeted action suggests that it could be a useful tool in veterinary medicine or agriculture for enhancing growth and improving feed efficiency in livestock.

In conclusion, Ipamorelin shows significant promise as a growth hormone-releasing agent due to its selective stimulation of growth hormone secretion. This raises its potential applications in animal husbandry, indicating a need for further research on its effects across different species.

PMID: 11713252 #

This article investigated the effects of Ipamorelin on growth hormone (GH) release in humans and how it interacts with growth hormone-releasing hormone (GHRH). The objective was to determine whether GHRH could enhance the GH-releasing effects of Ipamorelin in individuals.

The findings indicated that the GH-releasing effects of Ipamorelin were indeed potentiated when GHRH was administered alongside. This suggests a synergistic effect, where GHRH boosts the action of Ipamorelin, leading to a greater overall increase in growth hormone secretion.

In conclusion, the study highlights the efficacy of Ipamorelin as a growth hormone secretagogue while demonstrating that its effects can be enhanced by GHRH. This combination may have therapeutic implications for conditions related to growth hormone deficiency, warranting further exploration in clinical settings.